Navigation Links
Tailoring glioblastoma therapies: 1 size does not fit all
Date:2/6/2008

An upcoming G&D paper from Dr. Azad Bonni and colleagues at Harvard Medical School lends new insight into how the unique genetic signature of glioblastoma tumors affects treatment efficacy - a finding with promising hope for the therapeutic targeting of the leading cause of cancer-related deaths in the young and middle-aged population.

Dr. Bonni's group found that the transcription factor STAT3 has either a tumor promoting or tumor suppressive effect depending upon the genetic profile of the glioblastoma tumor.

Glioblastomas are the most common and aggressive type of adult brain cancer, with an annual incidence of approximately 13,000 in the United States, and an expected median survival rate of just over a year. STAT3 is a cytokine-activated transcription factor that has been previously reported to play a pro-oncogenic role in tumor development. Thus, much effort has been aimed at the development of STAT3 inhibitors as chemotherapeutic agents.

Dr. Bonni and colleagues now report that STAT3 can function as either a tumor suppressor or an oncoprotein. Using a mouse model system of two common genetic mutations in glioblastomas - PTEN deficiency or EGFRvIII activation -- the researchers show that PTEN regulates STAT3 tumor suppressor function, while STAT3 cooperates with the EGFRvIII oncoprotein to promote tumor growth.

Thus, the researchers convincingly demonstrate a need for effective therapies tailored to the unique genetic thumbprint of individual glioblastoma tumors. "These findings may change the way we approach not only glioblastoma but other types of cancer as well", says Azad Bonni, senior author of the study.


'/>"/>

Contact: Heather Cosel
coselpie@cshl.edu
Cold Spring Harbor Laboratory
Source:Eurekalert

Page: 1

Related medicine news :

1. Data Show SuperGens Multi-Targeted Tyrosine Kinase Inhibitor Demonstrates Pre-clinical Activity in Glioblastoma Multiforme
2. A fresh look at existing therapies: Researchers explore ways to teach approved drugs new tricks
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/18/2017)... ... July 19, 2017 , ... USHEALTH Group, Inc. has ... in the prestigious CEO World Awards®. The coveted annual CEO World Awards ... services, CEO case studies, corporate social responsibility, and milestones from every major industry ...
(Date:7/17/2017)... ... July 17, 2017 , ... In a ... during Pregnancy , studies take a closer look at maternal depression, its effects ... with one study showing newer medications may be safer choices. , The scientific ...
(Date:7/17/2017)... (PRWEB) , ... July 17, 2017 , ... McGraw Family ... Patient Care and Train Next Generation of Healthcare Clinicians , NORWALK, Connecticut – ... is continuing its legacy of investing in community health by pledging up to $3 ...
(Date:7/17/2017)... ... July 17, 2017 , ... Altec Products, ... DocLink Advanced Admin Training in Atlanta, Georgia. The four-day training session, ... will allow them to manage DocLink more efficiently and effectively. , Covering topics ...
(Date:7/17/2017)... ... 17, 2017 , ... Western University of Health Sciences has ... Education for the sixth consecutive year, and also made the Honor Roll for ... Lebanon, Oregon, was recognized in seven categories: Collaborative Governance, Compensation & Benefits, Job ...
Breaking Medicine News(10 mins):
(Date:7/5/2017)... 2017 Pace Analytical, a company of over 2,000 employees and a ... acquired ESC Lab Sciences, further solidifying their position as the top American owned ... ... CEO of Pace Analytical ... of Mt Juliet, TN , enhances Pace Analytical,s capability as ...
(Date:6/30/2017)... (AVACEN) announced the publication of new research in the peer-reviewed Fibromyalgia ... AVACEN Treatment Method to significantly reduce the widespread pain symptom ... ... ... to 400 million people worldwide according to The National Fibromyalgia Association. ...
(Date:6/20/2017)... HILLS, Calif. , June 20, 2017 SkylineDx ... the use of MMprofiler with SKY92, the company,s prognostic ... In a poster presentation at the 22 nd ... Madrid, Spain , SkylineDx researchers will demonstrate ... patients. In a separate e-poster presentation ...
Breaking Medicine Technology: